Adjuvants in cancer vaccination

Immunologic Adjuvant Research

Volumn , Issue , 2009, Pages 1-46

  Kircheis, Ralf ^a   Nechansky, Andreas ^b  

^a Meridian Biopharmaceuticals GmbH   (Austria)

^b Vela pharm Entwicklung u Laboranalytik GmbH   (Austria)

Author keywords

Adjuvant; Alum; AS02; BCG; Carbohydrate specific immune response; CpG; Cytokines; Detox B; ENHANZYN; GM CSF; Heat shock protein; IC31; IFNa; IL 12; IL 2; ISCOMS; LPS; MF59; MPL; QS 21; SialylTn

Indexed keywords

EID: 77958540224     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (165)

1. Aggerbeck, H; Fenger, C; Heron, I. Booster vaccination against diphtheria and tetanus in man. Comparison of calcium phosphate and aluminium hydroxide as adjuvants-II. Vaccine, 1995; 13(14): 1366-1374.
2. Antony, PA; Restivo, NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer and interleukin-2. J. Immunother, 2005; 28: 120-128.
3. Arellano, MK; Waller E. Granulocyte-macrophage-colony-stimulating factor and other cytokines: as adjuncts to cancer immunotherapy, stem cell transplantation, and vaccines. Curr Hematol Rep, 2004; 3(6):424-431.
4. Arina, A; Tirapu, I; Alfaro, C; et al. Clinical implications of antigen transfer mechanisms from malignant to dendritic cells, exploiting cross-priming. Exp Hemato, 2002; 30: 1355-1364.
5. Asai, T; Storkus, WJ; Whiteside, TL. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol, 2000; 7(2):145-154.
6. Atzpodien, J; Reitz, M; GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients. Cancer Biother Radiopharm, 2007; 22(4):551-555.
7. Aucouturier, J; Ganne, V; Laval, A; Efficacy and safety of new adjuvants. Ann New York Acad Sci, 2000; 916: 600-604.
8. Baldridge, JR; Crane, RT; Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 1999; 19: 103-107.
9. Banchereau, J; Steinman, RM; Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
10. Barrio, MM; de Motta, PT; Kaplan, J; von Euw, EM; Bravo, AI; Chacón, RD; Mordoh, J. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother. 2006; 29(4): 444-54
11. Belardelli, F; Ferrantini, M; Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 2002; 23: 201-208
12. Bins, A; Mallo, H; Sein, J; van den Bogaard, C; Nooijen, W; Vyth-Dreese, F; Nuijen, B; de Gast, GC; Haanen, JB. Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. J Immunother. 2007; 30(2): 234-239
13. Brandenburg, K; Lindner, B; Schromm, A; et al. Physicochemical characteristics of triacyl lipid A partial structure OM-174 in relation to biological activity. Eur J Biochem. 2000; 267: 3370-3377.
14. Brewer, JM; Conacher, M; Hunter, CA; et al. Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4-or IL-13-mediated signaling. J Immunol. 1999; 163: 6448-6454.
15. Brill, TH; Kübler, H; von Randenborgh, H; Fend, F; Pohla, H; Breul, J; Hartung, R; Paul, R; Schendel, DJ; Gansbacher, B. Allogeneic retrovirally transduced, IL-2-and IFN-gammasecreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial. Gene Med. 2007; 9(7): 547-560
16. Burkly, LC; Lo, D; Kanagawa, O; Brinster, RL; Flavell, RA. Nature. 1989; 342: 564-566
17. Burnet, FM. The concept of immune surveillance. Prog. Exp. Tumor Res. 1970; 13: 1-27.
18. Chianese-Bullock, KA; Pressley, J; Garbee, C; Hibbitts, S; Murphy, C; Yamshchikov, G; Petroni, GR; Bissonette, EA; Neese, PY; Grosh, WW; Merrill, P; Fink, R; Woodson, EM; Wiernasz, CJ; Patterson, JW; Slingluff, CL Jr. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol. 2005; 174(5):3080-3086.
19. Clerici, M; Shearer, GM; Clerici, E; Cytokine Dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the Th1/Th2 paradigm. J. Natl. Cancer Inst. 1998; 90: 261-263.
20. Colombo, MP; Ferrari, G; Stoppacciaro, A; et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 1991; 173: 889-897.
21. Connor, J; Bannerji, R; Saito, S; et al. Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J. Exp. Med. 1993; 177: 1127-1134.
22. Dranoff, G. GM-CSF-based cancer vaccines. Immunol Rev. 2002; 188: 147-154.
23. Dranoff, G. GM-CSF-secreting melanoma vaccines. Oncogene. 2003; 22(20): 3188-3192
24. Dranoff, G; Jaffee, E; Lazenby, A; et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulated potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA. 1993 90: 3539-3543.
25. Dredge, K; Marriott, JB; Todryk, SM; et al. Adjuvants and the promotion of Th1-type cytokines in tumor immunotherapy. Cancer Immunol Immunother. 2002; 51: 521-531.
26. Eggermont, AM; Suciu, S; Santinami, M; Testori, A; Kruit, WH; et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008; 372(9633):117-126.
27. Egilmez, NK; Kilinc, MO; Gu; T, Conway, TF. Controlled-release particulate cytokine adjuvants for cancer therapy. Endocr Metab Immune Disord Drug Targets. 2007; 7(4):266-270.
28. Fagerberg, J; Ragnhammar, P; Liljefors, M; Hjelm, AL; Mellstedt, H; Frodin, JE. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. Cancer Immunol. Immunother. 1996; 42: 81-87.
29. Fagerberg J, Frodin JE, Wigzell H, Mellstedt H. Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy? Cancer Immunol. Immunother. 37: 264-270, 1993.
30. Fagerberg, J; Hjelm, AL; Ragnhammar, P; et al. Tumor regression in monoclonal antibodytreated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 1995; 55: 1824-1827.
31. Fearon, ER; Pardoll, DM; Itaya, T; et al, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990; 60: 397-403.
32. Fung, PYS; Madej, M; Koganty, RR; Longenecker, BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. 1990; 50: 4308-4314.
33. Gansbacher, B; Bannerji, R; Daniels, B; et al. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long-lasting antitumor immunity. Cancer Res. 1990; 50: 7820-7825.
34. Gansbacher, B; Zier, K; Daniels, B; et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 1990b; 172: 1217-1224.
35. Gaughler, B; Van den Eynde, B; van der Bruggen, P; Romero, P; Gaforio, JJ; DePlaen, E; Lethe, B; Brasseur, F; Boon, T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp.Med. 1994; 179: 921-930.
36. Gilboa, E. The promise of cancer vaccines. Nat. Rev. Cancer. 2004; 4: 401-411.
37. Golumbek, PT; Azhari, EM; Jaffee, LM; et al. Controlled release, biodegradable cytokine deposits: a new approach in cancer vaccine design. Cancer Res. 1993; 53: 5841-5844.
38. Gilewski, TA; Ragupathi, G; Dickler, M; Powell, S; Bhuta, S; Panageas, K; Koganty, RR; Chin-Eng, J; Hudis, C; Norton, L; Houghton, AN; Livingston, PO. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res. 2007; 13(10):2977-2985.
39. Gilliam, AD; Watson, SA. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007; 7(3):397-404.
40. Glenn, GM; Rao, M; Matyas, GR; Alving, CR. Skin immunization made possible by cholera toxin. Nature. 1998; 391: 851.
41. Goedert, JJ; Cote, TR; Virgo, P; et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998; 351: 1833-1839.
42. Gupta, RK. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 1998; 32: 155-172.
43. Gupta, RK; Rost, BE; Relyveld, E; Siber, GR. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol. 1995; 6: 229-248.
44. Hanna, MG Jr; Hoover, HC Jr; Vermorken, JB; et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine. 2001; 19: 2576-2582.
45. Harris, JE; Ryan, L; Hoover, HC Jr; et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000; 18: 148-157.
46. Haurum, JS; Holer, IB; Arsequell, G; Neisig, A; Valencia, G; Zeuthen, J; Neefjes, J; Elliott, T. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J. Exp. Med. 1999; 190: 145-150.
47. He, Q; Mitchell, AR; Johnson, SL; Wagner-Bartak, C; Morcol, T; Bell, SJ. Calcium phosphate nanoparticle adjuvant. Clin Diagn Lab Immunol. 2000; 7(6):899-903.
48. Heath, WR; Carbone, FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001; 19: 47-64.
49. Heineman, TC; Clements-Mann, ML; Poland, GA; et al. A randomized controlled study in adults of immunogenicity oa novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 1999; 17: 2769-2778.
50. Holmberg, LA; Oparin, DV; Gooley, T; Lilleby, K; Bensinger, W; Reddish, MA; MacLean, GD; Longenecker, BM; Sandmaier, BM. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant. 2000; 25(12):1233-1241.
51. Holmberg, LA; Oparin, DV; Gooley, T; Sandmaier, BM. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clin Breast Cancer. 2003; 3 Suppl 4: S144-1451.
52. Holmberg, LA; Sandmaier, BM. Theratope vaccine (STn-KLH). Expert Opin Biol Ther. 2001; 1(5):881-891.
53. Hoover, HC Jr; Brandhorst, JS; Peters, LC; et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol. 1993; 11: 390-399.
54. Huang, A.Y.C; Golumbek, P; Ahmadzadeh, M; Jaffee, E; Pardoll, D; Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994; 264: 961-965.
55. Ibrahim, NK; Murray, JL. Clinical development of the STn-KLH vaccine (Theratope). Clin Breast Cancer. 2003; 3 Suppl 4: S139-143.
56. Itzkowitz, SH; Bloom, EJ; Kokal, WA; Modin, G; Hakomori, S; Kim, YS. Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990; 66: 1960-1966.
57. Itzkowitz, SH; Yuan, M; Montgomery, CK; Kjeldsen, T; Takahashi, HK; Bigbee, WL; Kim, YS. Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 1989; 49: 197-204.
58. Jaffee, EM; Thomas, MC; Huang, AYC; et al. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. Journal of Immunotherapy. 1996; 19: 176-183.
59. Jurk, M; Vollmer, J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs. 2007; 21(6):387-401.
60. Kayaga, J; Souberbielle, BE; Sheikh, N; Morrow, WJW; Scott-Taylor, T; Vile, R; Dalgleish, AG. Antitumor activity against B16F10 melanoma with a GM-CSF secreting allogeneic tumor cell vaccine. Gene Ther. 1999; 6: 1475-1481.
61. Kammula, US; White, DE; Rosenberg, SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998; 83: 797-805.
62. Kawakami, Y; Eliyahu, S; Delgado, CH; Robbins, PF; Rivoltini, L; Topalian SL; Miki, T; Rosenberg, SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 1994; 91: 3515-3519.
63. Kenney, RT; Regina Rabinovich, N; Pichyangkul, S; Price, VL; Engers, HD. 2nd meeting on novel adjuvants currently in/close to human clinical testing. World Health Organization-Organization Mondiale de la Santé Fondation Mérieux, Annecy, France, 5-7 June 2000. Vaccine. 2002; 20(17-18): 2155-2163
64. Kensil, CR; Kammer, R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin Investig Drugs. 1998; 7(9): 1475-1482
65. Kim, YJ; Wang, P; Navarro-Villalobos, M; Rohde, BD; Derryberry, J; Gin, DY. Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi. J Am Chem Soc. 2006; 128(36):11906-11915.
66. Kircheis, R; Küpcü, Z; Wallner, G; Rössler, V; Schweighoffer, T; Wagner, E. Interleukin-2 gene-modified allogeneic melanoma cell vaccine can induce cross-protection against syngeneic tumors in mice. Cancer Gene Ther. 2000; 7: 870-878.
67. Kircheis, R; Küpcü, Z; Wallner, G; Wagner, E. Cytokine gene-modified tumor cells for prophylactic and therapeutic vaccination: IL-2, IFNγ, or combination IL-2 + IFNγ. Cytokines Cell Mol Ther. 1998; 4: 95-103.
68. Kircheis, R; Vondru, P; Nechansky, A; Ohler, R; Loibner, H; Himmler, G; Mudde, GC. SialylTn-mAb17-1A carbohydrate-protein conjugate vaccine: effect of coupling density and presentation of SialylTn. Bioconjug Chem. 2005; 16(6):1519-1528.
69. Kircheis, R; Vondru, P; Zinöcker, I; Häring, D; Nechansky, A; Loibner, H; Mudde, GC. Immunization of Rhesus monkeys with the conjugate vaccine IGN402 induces an IgG immune response against carbohydrate and protein antigens, and cancer cells. Vaccine. 2006; 24: 2349-2357.
70. Kircheis, R; Siegl, P; Grunt, S; Halanek, N; Loibner, H; Mudde, GC; Nechansky, A. Immunization of Rhesus monkeys with a SialylTn-mAb17-1A conjugate vaccine coformulated with QS-21 induces a temporary systemic cytokine release and NK cytotoxicity against tumor cells. Cancer Immunol Immunother. 2007; 56(6):863-873.
71. Klinman, DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2003; 2: 305-315.
72. Knight, B.C; Souberbielle, B.E; Rizzardi, G.P; Ball, S.E; Dalgleish, A.G; Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res. 1996; 6: 1-8.
73. Koeller, JM. Biologic response modifiers: the interferon alfa experience. Am J Hosp Pharm. 1989; 46(11 Suppl 2): 11-15.
74. Koppenhagen, FJ; Küpcü, Z; Wallner, G; Crommelin, DJ; Wagner, E; Storm, G; Kircheis, R. Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for genetransfected tumor cells. Clin Cancer Res. 1998; 4(8):1881-1886.
75. Kuang, M; Peng, BG; Lu, MD. et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 2004; 10: 1574-1579.
76. Jiang, D; Premachandra, GS; Johnston, C; Hem, SL. Structure and adsorption properties of commercial calcium phosphate adjuvant. Vaccine. 2004; 23(5):693-698.
77. Livingston, PO; Wong, GYC; Adluri, S; Tao, Y; Padavan, M; Parente, R; Hanlon, C; Helling, F; Ritter, G; Oettgen, HF; Old, LJ. Improved survival in AJCC stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 1994; 12: 1036-1044.
78. Loibner, H; Eller, N; Groiss, F. et al. A randomized placebo-controlled phase II study with the cancer vaccine IGN101 in patients with epithelial solid organ tumors (IGN101/2-01). Proc Am Soc Clin Oncol 2004; 22: 14.
79. Lonchay, C; van der Bruggen, P; Connerotte, T; Hanagiri, T; Coulie, P; Colau, D; Lucas, S; Van Pel, A; Thielemans, K; van Baren, N; Boon T. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A. 2004; 101(2):14631-14638.
80. Maass, G; Schmidt, W; Berger, M; Schilcher, F; Koszik, F; Schneeberger, A; Stingl, G; Birnstiel, M.L; Schweighoffer, T. Priming of tumor-specific T-cells in the draining lymph nodes after immunization with interleukin-2 secreting tumor cells: Three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA 1995; 92: 5540-5544.
81. MacLean, GD; Reddish, MA; Koganty, RR. et al. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol. 1996; 19: 59-68.
82. MacLean, GD; Reddish, MA; Koganty, RR; Longenecker, BM. Antibodies against mucinassociated SialylTn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. 1996; 19: 59-68.
83. Marchand, M; Punt, CJ; Aamdal, S; Escudier, B; Kruit, WH; Keilholz, U; Håkansson, L; van Baren, N; Humblet, Y; Mulders, P; Avril, MF; Eggermont, AM; Scheibenbogen, C; Uiters, J; Wanders, J; Delire, M; Boon, T. Stoter GImmunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer. 2003; 39(1):70-77.
84. Marincola, FM; Jaffee, EM; Hicklin, DJ; Ferrone, S. Escape of human tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000; 74: 181-273.
85. Marotta, G; Frassoldati, A; Zinzani, P; Annino, L; Brugiatelli, M; Ambrosetti, A; Lenoci, M; Federico, M; Foa R, Lauria F; Italian Cooperative group for HCL (ICGHCL). Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. Eur J Haematol. 2006; 77(2):109-113.
86. Matzinger, P. The danger model: a renewed sense of self. Science 2002; 296: 301-305.
87. Mazzaferro, V; Coppa, J; Carrabba, MG. et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 2003; 9: 3235-3245.
88. Mellstedt, H; Fagerberg, J; Frodin, JE. et al. Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors. Curr Opin Hematol. 1999; 6: 169-175.
89. Miles, D; Papazisis, K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer. 2003; 3(4):134-138.
90. Miles, DW; Towlson, KE; Graham, R; Reddish, M; Longenecker, BM; Taylor-Papadimitriou, J; Rubens, RD. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer. 1996; 74(8):1292-1296.
91. Miller, JF; Morahan, G; nad Allison J. Cold Spring Harb. Symp. Quant. Biol. 1989; 2: 807-813.
92. Mosolits, S; Ullenhag, G; Mellstedt, H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol. 2005; 16(6):847-862.
93. Naito, Y; Saito, K; Shiiba, K. et al. CD8+ T cells infiltrated within cancer cell nests as prognostic factor in human colorectal cancer. Cancer res. 1998; 58: 3491-3494.
94. Nakano, O; Sato, M; Naito, Y. et al. Proliferative activity of intratumoral CD8+ Tlymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001; 61: 5132-5236.
95. Nauts, H; Fowler, G; Bogatko, F. A review of the influence of bacterial infection and of bacterial products (Coley's toxin) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med. Scand. 1953; 144: 1-103.
96. Nemunaitis, J; Jahan, T; Ross, H; Sterman, D; Richards, D; Fox, B; Jablons, D; Aimi, J; Lin, A. Hege K.Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 2006; 13(6):555-562.
97. Noguchi Y, Richards EC, Chen YT, Old LJ. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci U S A. 92(6):2219-23, 1995.)
98. Ochsenbein, AF; Sierro, S; Odermatt, B; Pericin, M; Karrer, U; Hermans, J; Hemmi, S; Hengartner, H; Zinkernagel, RM. Roles of tumor location, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411: 1058-1064.
99. Ohashi, PS; Oehen, S; Buerki, K; Pircher, H; Ohashi, CT; Odermatt, B; Malissen, B; Zinkernagel, RM; Hengartner, H. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell. 1991; 65: 305-317.
100. Panelli, MC; White, R; Foster, M; Martin, B; Wang, E; Smith, K; Marincola, FM. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J. Translational Medicine. 2004; 2: 17-31.
101. Pardoll, DM. Paracrine cytokine adjuvants in cancer immunotherapy. Ann. Rev. Immunol. 1995; 13: 399-415.
102. Parmiani, G; De Filippo, A; Pilla, L; Castelli, C; Rivoltini, L. Heat shock proteins gp96 as immunogens in cancer patients. Int J Hyperthermia. 2006; 22(3):223-227.
103. Pham, HL; Ross, BP; McGeary, RP; Shaw, PN; Hewavitharana, AK; Davies, NM. Saponins from Quillaja saponaria Molina: isolation, characterization and ability to form immuno stimulatory complexes (ISCOMs). Curr Drug Deliv. 2006; 3(4):389-397.
104. Plautz, G.E; Yang, Z.-Y; Wu, B.-Y; Gao, X; Huang, L; Nabel, G.J. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad. Sci. USA. 1993; 90: 4645-4649.
105. Porgador, A; Gansbacher, B; Bannerji, R. et al. Antimetastatic vaccination of tumor-bearing mice with IL-2 gene-inserted tumor cells. Int. J. Cancer. 1993; 53: 471-477.
106. Portielje, JE; Gratama, JW; van Ojik, HH; Stoter, G; Kruit, WH. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother. 2003; 52(3):133-144.
107. Przepiorka, D; Srivastava, PK. Heat shock protein--peptide complexes as immunotherapy for human cancer. Mol Med Today. 1998; 4(11):478-84.
108. Ragupathi, G; Cappello, S; Yi, SS; Canter, D; Spassova, M; Bornmann, WG; Danishefsky, SJ; Livingston, PO. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine. 2002; 20(7-8): 1030-1038.
109. Ragupathi, G; Koide, F; Livingston, PO; Cho, YS; Endo, A; Wan, Q; Spassova, MK; Keding, SJ; Allen, J; Ouerfelli, O; Wilson, RM; Danishefsky, SJ. Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates. J Am Chem Soc. 2006; 128(8):2715-2725.
110. Ramesh, M; Turner, LF; Yadav, R; Rajan, TV; Vella, AT; Kuhn, LT. Effects of the physicochemical nature of two biomimetic crystals on the innate immune response. Int Immunopharmacol. 2007; 7(13):1617-1629.
111. Rayman, P; Wesa, AK; Richmond, AL; Das, T; Biswas, K; Raval, G; Storkus, WJ; Tannenbaum, C; Novick, A; Bukowski, R; Finke, J. Effect of renal cell carcinomas on the development of type-1 T-cell responses. Clin. Cancer Res. 2004; 10: 6360-6366.
112. Reddish, MA; MacLean, GD; Poppema, S. et al. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol Immunother. 1996; 42: 303-309.
113. Riethmuller, G; Schneider-Gadicke, E; Schlimok, G; Schmiegel, W; Raab, R; Hoffken, K; Gruber, R; Pichlmaier, H; Hirsche, H; Pichlmayr, R. et a. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study group. Lancet. 1994; 343: 1172-1174.
114. Rodolfo, M; Bassi, C; Salvi, C; Parmiani, G. Therapeutic use of a long-term cytotoxic T cell line recognizing a common tumor-associated antigen: the pattern of in vitro reactivity predicts the in vivo effect on different tumors. Cancer Immunol. Immunother. 1991; 34: 53-62.
115. Rosenberg, SA. Interleukin 2 for patients with renal cancer. Nat Clin Pract Oncol. 2007; 4(9): 497.
116. Rosenberg, SA; Yang, JC; Topalian, SL; Schwartzentruber, DJ; Weber, JS; Parkinson, DR; Seipp, CA; Einhorn, JH; White, DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin. JAMA. 1994; 271(12):907-913.
117. Rosenstein, M; Ettinghausen, SE; Rosenberg, SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986; 137(5):1735-1742.
118. Sabbatini, PJ; Ragupathi, G; Hood, C; Aghajanian, CA; Juretzka, M; Iasonos, A; Hensley, ML; Spassova, MK; Ouerfelli, O; Spriggs, DR; Tew, WP; Konner, J; Clausen, H; Abu Rustum, N; Dansihefsky, SJ; Livingston, PO. Pilot study of a heptavalent vaccinekeyhole limpet hemocyanin conjugate plus QS-21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res. 2007; 13(14):4170-4177.
119. Salgia, R; Lynch, T; Skarin, A; Lucca, J; Lynch, C; Jung, K; Hodi, FS; Jaklitsch, M; Mentzer, S; Swanson, S; Lukanich, J; Bueno, R; Wain, J; Mathisen, D; Wright, C; Fidias, P; Donahue, D; Clift, S; Hardy, S; Neuberg, D; Mulligan, R; Webb, I; Sugarbaker, D; Mihm, M; Dranoff, G. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003; 21(4):624-630.
120. Samonigg, H; Wilders-Truschnig, M; Kuss, I. et al. A double-blind randomized-phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer. J Immunother. 1999; 22: 481-488.
121. Sanchez, EQ; Marubashi, S; Jung, G; et al. De novo tumors after liver transplantation: A single institution experience. Liver Transpl. 2002; 8: 285-291.
122. Schellack, C; Prinz, K; Egyed, A; Fritz, JH; Wittmann, B; Ginzler, M; Swatosch, G; Zauner, W; Kast, C; Akira, S; von Gabain, A; Buschle, M; Lingnau, K. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine. 2006; 24(26):5461-5472.
123. Schiller, JH; Pugh, M; Kirkwood, JM; Karp, D; Larson, M; Borden, E. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin. Cancer Res. 1996; 2: 29-36.
124. Schmidt, W; Schweighoffer, T; Herbst, E. et al. Cancer vaccines: The interleukin 2 dosage effect. Proc. Natl. Acad. Sci. USA. 1995; 92: 4711-4714.
125. Schumacher, K; Haensch, W; Roefzaad, C. et al. Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res. 2001; 61: 3932-3936.
126. Seeber, SJ; White, JL; Hem, SL. Solubilization of aluminium-containing adjuvants by constituents of interstitial fluid. J. Parenteral Sci. Technol. 1991; 45: 1412-1416.
127. Settaf, A; Salzberg, M; Groiss, F; Eller, N; Schuster, M; Himmler, G; Kundi, M; Eckert, H; Loibner, H. A randomized placebo-controlled Phase II study with the cancer vaccine IGN101 in patients with epithelial cancers. iSBTc 19th Annual Meeting, San Franscisco, 4-7. 11. 2004
128. Singhal, A; Fohn, M; Hakomori, S-I. Induction of a α-N-acetylgalactosamine-Oserine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res. 1991; 51: 1406-1411.
129. Sjolander, A; Drane, D; Maraskovsky, E. Immune responses to ISCOM® formulations in animal and primate models. Vaccine. 2001; 19: 2661-2665.
130. Seubert, A; Monaci, E; Pizza, M; O'Hagan, DT; Wack, A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol. 2008; 180(8):5402-5412.
131. Slingluff, CL Jr; Yamshchikov, G; Neese, P; Galavotti, H; Eastham, S; Engelhard, VH; Kittlesen, D; Deacon, D; Hibbitts, S; Grosh, WW; Petroni, G; Cohen, R; Wiernasz, C; Patterson, JW; Conway, BP; Ross, WG. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001; 7(10):3012-3024.
132. Slovin, SF; Keding, SJ; Ragupathi, G. Carbohydrate vaccines as immunotherapy for cancer. Immunol Cell Biol. 2005; 83(4):418-428.
133. Slovin, SF; Ragupathi, G; Fernandez, C; Diani, M; Jefferson, MP; Wilton, A; Kelly, WK; Morris, M; Solit, D; Clausen, H; Livingston, P; Scher, HI. A polyvalent vaccine for highrisk prostate patients: "are more antigens better?" Cancer Immunol Immunother. 2007; 56(12): 1921-1930.
134. Slovin, SF; Ragupathi, G; Fernandez, C; Jefferson, MP; Diani, M; Wilton, AS; Powell, S; Spassova, M; Reis, C; Clausen, H; Danishefsky, S; Livingston, P; Scher, HI. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21. Vaccine. 2005; 23(24):3114-3122.
135. Soiffer, R; Hodi, FS; Haluska, F; Jung, K; Gillessen, S; Singer, S; Tanabe, K; Duda, R; Mentzer, S; Jaklitsch, M; Bueno, R; Clift, S; Hardy, S; Neuberg, D; Mulligan, R; Webb, I; Mihm, M; Dranoff, G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviralmediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003; 21(17):3343-3350.
136. Sondak, VK; Sabel, MS; Mulé, JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res. 2006; 12(7 Pt 2): 2337-2341.
137. Tamura, S. et al., Synergistic action of cholera toxin B subunit (and Escherichia coli heatlabile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenca vaccine. Vaccine. 1994; 12: 419-426.
138. Tamura, Y; Peng, P; Liu, K; Daou, M; Srivastava, PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 1997; 278: 117-120.
139. Tartour, E; Benchetrit, F; Haicheur, N. et al. Synthetic and natural non-live vectors: rationale for their clinical development in cancer vaccine protocols. Vaccine 2002; 20(4):32-39.
140. Tenderich, G; Deyerliong, W; Schulz, U. et al., Malignantneoplastic disorders following long-term immunosuppression after orthotopic heart transplantation. Transplant. Proc. 2001; 33: 3653-3655.
141. Thomas, M.C; Greten, T.F; Pardoll, D.M; Jaffee, E.M. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Human Gene Ther. 1998; 9: 835-843.
142. Travers, PJ; Arklie, JL; Trowsdale, J; Patillo, RA; Bodmer, WF. Lack of expression of HLAABC antigens in choriocarcinoma and other human tumor cell lines. Natl. Cancer Inst. Monogr. 1982; 60: 175-180.
143. Trinchieri, G. Function and clinical use of interleukin-12. Curr Opin Hematol. 1997; 4(1):59-66.
144. Udono, H; Levey, DL; Srivastava, PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci U S A. 1994; 91: 3077-3081.
145. Ulanova, M; Tarkowski, A; Hahn-Zoric, M; Hanson, LA. The common vaccine adjuvant aluminium hydroxide upregulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. 2001; 69: 1151-1159.
146. Ullenhag, GJ; Frödin, JE; Mosolits, S; Kiaii, S; Hassan, M; Bonnet, MC; Moingeon, P; Mellstedt, H; Rabbani, H. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVACKSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin Cancer Res. 2003; 9(7):2447-2456.
147. Uyl-de Groot, CA; Vermorken, JB; Hanna, MG Jr; Verboom, P; Groot, MT; Bonsel, GJ; Meijer, CJ; Pinedo, HM. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005; 23(17-18): 2379-2387.
148. Van der Bruggen, P; Traversari, C; Chomez, P; Lurquin, C; DePlaen, E; Van den Eynde, B; Knuth, A; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
149. Van Slooten, ML; Kircheis, R; Koppenhagen, FJ; Wagner, E; Storm, G. Liposomes as cytokine-supplement in tumor cell-based vaccines. Int J Pharm. 1999; 183(1):33-36.
150. Vantomme, V; Dantinne, C; Amrani, N; Permanne, P; Gheysen, D; Bruck, C; Stoter, G; Britten, CM; Keilholz, U; Lamers, CH; Marchand, M; Delire, M; Guéguen, M. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother. 2004; 27(2):124-135.
151. Vázquez-Lavista, LG; Flores-Balcázar, CH; Llorente, L. [The bacillus Calmette-Guérin as immunomodulator in bladder cancer][Article in Spanish] Rev Invest Clin. 2007; 59(2): 146-152.
152. Vermorken, JB; Claessen, AM; van Tinteren, H; et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999; 353: 345-350.
153. Waller, EK. The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist. 2007; 12(2):22-26.
154. Wang, P; Kim, YJ; Navarro-Villalobos, M; Rohde, BD; Gin, DY. Synthesis of the potent immunostimulatory adjuvant QS-21A. J Am Chem Soc. 2005; 127(10):3256-3257.
155. Watson, SA; Michaeli, D; Grimes, S; Morris, TM; Robinson, G; Varro, A; Justin, TA; Hardcastle, JD. Gastrimmune raises antibodies that neutralize amidated and glycineextended gastrin-17 and inhibit the growth of colon cancer. Cancer Res. 1996; 56: 880-885.
156. Werdelin, O; Meldal, M; Jensen, T. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc. Natl. Acad. Sci. USA. 2002; 99: 9611-9613.
157. Werther, JL; Rivera-MacMurray, S; Bruckner, H; Tatematsu, M; Itzkowitz, SH. Mucinassociated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. Br. J. Cancer 1994; 69: 613-616.
158. Yamamura, M; Modlin, RL; Ohmen, JD; and Moy, RL. Local expression of antiinflammatory cytokines in cancer. J. Clin. Invest. 1993; 91: 1005-1010.
159. Yang, JC; Sherry, RM; Steinberg, SM; Topalian, SL; Schwartzentruber, DJ; Hwu, P; Seipp, CA; Rogers-Freezer, L; Morton, KE; White, DE; Liewehr, DJ; Merino, MJ; Rosenberg, SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003; 21(16):3127-3132.
160. Zatloukal, K; Schneeberger, A; Berger, M. et al. Elicitation of a systemic and protective antimelanoma immune response by an IL-2 based vaccine. J. Immunol. 1995; 154: 3406-3419.
161. Zhang, H; Zhang, S; Cheung, NK; Ragupathi, G; Livingston, PO. Antibodies can eradicate cancer micrometastases. Cancer Res. 1998; 58: 2844-2849.
162. Zhang, L; Conejo-Garcia, JR; Katsaros, D. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003; 348: 203-213.
163. Zhang, S; Zhang, SH; Cordon-Cardo, C; Reuter, VE; Singgal, AK; Lloyd, KO; Livingston, PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens. Int. J. Cancer. 1997; 73: 50-56.
164. Zhang, S; Walberg, LA; Ogata, S; Itzkowitz, SH; Koganty, RR; Reddish, M; Gandhi, SS; Longenecker, BM; Lloyd, KO; Livingston, PO. Immune sera and monoclonal antibodies define two configurations for the sialylTn tumor antigen. Cancer Res. 1995; 55: 3364-3368.
165. Zurbriggen, R; Glück, R. Immunogenicity of IRIV-versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice. Vaccine 1999; 17: 1301-1305.